Our Products News
-
Ribo Discloses Positive Data from Vortosiran Phase IIa Trial - World’s First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery DiseaseRibo Discloses Positive Data from Vortosiran Phase IIa Trial - World’s First Clinical Data on siRNA-Mediated FXI Inhibition Following Multiple Dosing in Patients with Coronary Artery DiseaseJuly 22, 2026 -
Breaking Preview: Ribo to Unveil Global First Phase IIa Clinical Data of Lead Asset Vortosiran at CPIC, Followed by Dedicated Data Briefing with Live StreamingRibo will present at the inaugural CPIC on July 22, where it will disclose for the first time Phase IIa clinical data of vortosiran (RBD4059) for CAD.July 8, 2026 -
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASHRibo and Madrigal announce the nomination of the first candidate drug within their siRNA partnership, marking a key milestone and enabling the immediate initiation of IND-enabling studies.July 2, 2026 -
Ribo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic DiseaseRibo Announces Phase 2 Clinical Trial Submission to EMA, Further Advancing siRNA Therapeutics in Thromboembolic DiseaseMay 28, 2026 -
Ribo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AIRibo Announces Strategic Collaboration with Insilico Medicine to Accelerate siRNA Drug Development Driven by AIMay 12, 2026 -
Ribo Advances Clinical Development of FXI siRNA vortosiran with EMA Phase 2b CTA Submission in Venous Thromboembolism, ORBIT-XI-VTERibo has submitted a Phase 2b CTA to the EMA for vortosiran (RBD4059) to prevent venous thromboembolism.May 11, 2026